Search

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins – molecules that transport fat in blood – which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT

A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.

A shot of a liver-produced hormone called FGF21 sobered up mice that had passed out from alcohol, allowing them to regain consciousness and coordination much faster than those that didn’t receive this treatment, UT Southwestern researchers report in a new study.

Ravikanth Maddipati, M.D., Assistant Professor of Internal Medicine and in Children’s Medical Center Research Institute at UT Southwestern, has been awarded $1.5 million from the National Institutes of Health (NIH) to support research investigating positional heterogeneity in cancer, or how tumors

UT Southwestern has received the 2020 Health Professions Higher Education Excellence in Diversity (HEED) Award from INSIGHT Into Diversity magazine, the oldest and largest diversity-focused publication in higher education.

Jinming Gao, Ph.D., Professor of Biomedical Engineering, Cell Biology, Otolaryngology – Head and Neck Surgery, and Pharmacology at UT Southwestern Medical Center, has been selected as a fellow of the National Academy of Inventors (NAI) in recognition of his efforts to develop innovative

Researchers with the Peter O’Donnell Jr. Brain Institute at UT Southwestern have identified a new protein implicated in cell death that provides a potential therapeutic target that could prevent or delay the progress of neurodegenerative diseases following a stroke.

Expanded telehealth services at UT Southwestern have proved effective at safely delivering patient care during the pandemic, leading to an increase in patients even in specialties such as plastic surgery, according to a new study.

Elevated calcium levels in the blood – a complication of kidney cancers known as hypercalcemia – may be successfully treated with a class of medications called HIF-2 inhibitors developed by UT Southwestern Medical Center, a new study shows. The findings, published in Cancer Discovery by a team at

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center more than $18.4 million for cancer research and faculty recruitment.